A prostate cancer diagnosis comes with a lot of information and many decisions to make. One of the first choices is whether to monitor the cancer or start treatment right away. This decision depends on the cancer’s grade, PSA level, tumor stage, and what matters most to you in daily life.
The main options for localized prostate cancer are active surveillance, surgery (radical prostatectomy), and radiation therapy. Hormone therapy is sometimes added to radiation for intermediate- or high-risk disease. The table below shows the key differences.
| Axis | Active Surveillance | Radical Prostatectomy | Radiation Therapy |
|---|---|---|---|
| Typical candidates | Very low-, low-, and selected favorable intermediate-risk cancers (Grade Group 1-2, PSA generally below 10-20 ng/mL) | Localized cancer in men who are healthy enough for surgery; all risk groups considered depending on extent of disease | Localized to locally advanced cancer; both low- and high-risk tumors; external beam or brachytherapy options available |
| Core approach | Monitoring with periodic PSA tests, digital rectal exam, imaging, and biopsy; treatment deferred unless the cancer shows signs of change | Surgical removal of the entire prostate gland and some surrounding tissue | Directing radiation at the prostate to destroy cancer cells; delivered externally over several weeks or internally via seed implants |
| Monitoring or treatment schedule | PSA approximately every 6 months, digital rectal exam every 12 months, biopsy every 1 to 3 years | One-time procedure; follow-up PSA checks at regular intervals afterward | Multiple daily sessions over several weeks (EBRT), or a single seed implant procedure (brachytherapy) |
| Common side effect concerns | Psychological burden of living with an unremoved cancer; risk of delayed treatment if progression is missed | Urinary leakage and erectile dysfunction are among the most frequently reported concerns after prostate removal | Bladder irritation, increased urinary frequency, bowel changes, and possible effects on erectile function over time |
| Can you move to active treatment later? | Yes – surveillance allows a transition to surgery or radiation if monitoring shows cancer progression | Prostate removal is permanent; additional therapies may be used if cancer recurs | Re-treating the prostate is limited; additional options exist if the cancer returns after radiation |
Table sources: American Cancer Society – Active Surveillance; American Cancer Society – Treatment by Stage and Risk Group; National Cancer Institute – Prostate Cancer Treatment PDQ.
Understanding Your Risk Group and Gleason Score
Before you choose a treatment, your care team will place your cancer in a risk group. In the United States, doctors usually use the system from the National Comprehensive Cancer Network (NCCN). It draws on three key measurements.
- PSA level – prostate-specific antigen, measured in nanograms per milliliter (ng/mL) from a blood sample. A PSA below 10 ng/mL suggests low-risk disease. A PSA above 20 ng/mL suggests high-risk disease.
- Grade Group (Gleason score) – this score describes how different the cancer cells look from normal prostate cells. Grade Group 1 (Gleason score 6 or less) means cells look close to normal. Grade Group 5 (Gleason score 9-10) means cells look very abnormal. According to Mayo Clinic, these are the two ends of the scale.
- Clinical T stage – how far the primary tumor has grown. Stage T1 means the tumor cannot be felt on examination. Stage T3 means the tumor has grown outside the prostate capsule.
According to the American Cancer Society, very low-risk cancer typically means Grade Group 1 and PSA below 10 ng/mL with limited biopsy involvement. High-risk cancer has at least one of these features: Grade Group 4 or 5, PSA above 20 ng/mL, or tumor growth outside the prostate. Your risk group directly shapes which options your team will offer and how urgently treatment is recommended.
What Active Surveillance Involves
Active surveillance is not just waiting and doing nothing. It is a structured monitoring program to detect any sign that the cancer is growing or changing, so treatment can start if needed.
A typical active surveillance schedule includes: a PSA blood test about every 6 months, a digital rectal exam (DRE) about once a year, and a prostate biopsy every 1 to 3 years. Your doctor will adjust the timing to your situation. Some centers also use multiparametric MRI (mpMRI) as a regular part of monitoring to reduce the need for repeat biopsies.
Active surveillance is generally recommended for men with very low-risk or low-risk cancer. It may also be considered for some men with favorable intermediate-risk disease – specifically those with a Grade Group 2 tumor with less than 10 percent Gleason pattern 4 tissue in the biopsy cores. Your doctor will tell you if your biopsy results match the criteria for surveillance.
A long-term study found that 99.7 percent of men on active surveillance did not die from their cancer. The study also found that about 35 percent of men eventually moved to active treatment, usually because they wanted to or because the biopsy showed the cancer was progressing. This shows that active surveillance is a starting point, not permanent. Moving to treatment later is a normal and planned option.
The main challenge with surveillance is the stress of living with untreated cancer. Some men find periodic monitoring manageable; others experience significant anxiety between tests. Either response is reasonable. Many cancer centers offer nurse navigator services and psychology support for men who find the uncertainty stressful.
Treatment Options Explained
Radical Prostatectomy
Radical prostatectomy is surgery to remove the entire prostate gland along with some surrounding tissue. It can be performed as open surgery, laparoscopic surgery, or robot-assisted laparoscopic surgery. According to the National Cancer Institute, radical prostatectomy is a standard treatment for cancer that is still within the prostate. If the cancer has reached nearby lymph nodes, those may also be removed during the same procedure.
Urinary leakage (incontinence) and difficulty achieving erections are among the most frequently reported side effects. Nerve-sparing surgical techniques can protect the nerves that control erections when the cancer’s location allows it. Getting urinary control back can take weeks to months, and results vary from person to person and between hospitals. The article Urinary Continence Recovery After Prostatectomy on this site covers pelvic floor rehabilitation strategies in detail.
Radiation Therapy
Radiation therapy for prostate cancer comes in two main forms. External beam radiation therapy (EBRT) uses a machine to aim targeted beams at the prostate over several weeks. Stereotactic body radiation therapy (SBRT) delivers higher doses in fewer sessions – sometimes just five treatments. Brachytherapy places radioactive seeds directly inside the prostate in a short procedure, where they release radiation to the surrounding tissue.
According to Cancer Research UK, cure rates for low-risk localized cancer treated with radiation are similar to those achieved with radical prostatectomy. Side effects can include bladder irritation, increased urinary frequency, changes in bowel habits, and possible gradual effects on erectile function.
Hormone Therapy (Androgen Deprivation Therapy)
Prostate cancer cells typically rely on testosterone to grow. Androgen deprivation therapy (ADT) reduces testosterone levels in the body, either through injectable or oral medications that suppress hormone signals, or less commonly through surgical removal of the testes. ADT is not usually used alone for localized low-risk disease. It is commonly added to radiation for intermediate- and high-risk cancers to improve cancer control. Standard ADT use alongside radiation ranges from about 4 to 6 months for favorable intermediate-risk disease to 2 to 3 years for high-risk disease, though your oncologist will define the right duration for your case.
ADT causes side effects, including hot flashes, fatigue, bone loss, and changes to body composition over time. Men starting long-term ADT should discuss bone health monitoring with their care team early. This site’s article on Estrogen Rebalancing After Prostate Cancer ADT addresses some of the hormonal shifts that occur during androgen suppression, and Prostate Cancer and Androgen Deprivation Therapy: Bone Health, Vitamin D Dosing, and Resistance Training covers strategies that may support bone density during treatment.
Weighing Side Effects Against Cancer Control
Every treatment option has trade-offs. The goal is to match treatment to your cancer risk while keeping your quality of life priorities in mind. A man who wants to keep sexual function might choose differently than a man who wants the prostate removed quickly. These are personal values, and the right choice is different for different people.
Talk with your doctors about what daily life might look like during and after each option. This is one of the most important conversations you can have. Ask about side effect rates at your center, not just published averages, which may not match your center’s results.
Integrative Support: What Has Been Studied
Some men ask if lifestyle changes or supplements can help with monitoring or treatment. Researchers have studied exercise, diet, and supplements in prostate cancer, but no supplement can replace surgery, radiation, or surveillance. Regular exercise is one of the lifestyle factors that researchers have studied most in prostate cancer survivors. Talk with your care team before adding any supplement or product to your routine. You can browse Oncostore’s selection of Integrative Oncology products to review what is available.
Questions to Ask Your Oncology Team
Consider writing these questions down before your next appointment. You do not need to cover all of them in a single visit.
- What is my exact risk group? Ask your doctor to name your Grade Group, PSA level, and clinical T stage, and explain what each means for your specific situation.
- Am I a candidate for active surveillance? Ask for the specific criteria that place you in or out of the surveillance path, and what early sign would trigger a shift to treatment.
- If I choose surveillance, what is the monitoring schedule? Clarify how often PSA tests, DREs, and biopsies will occur, and what PSA rise or biopsy finding would prompt a treatment discussion.
- What are the cancer control outcomes for each treatment option at this center? Ask your center for their outcome data, not just published averages.
- What are the most common side effects for men with my profile? Focus on side effects relevant to your age, your baseline urinary and sexual function, and any other health conditions you have.
- Should I get a second opinion? Most oncologists support second opinions for newly diagnosed cancer. Larger cancer centers often have multidisciplinary tumor boards that review complex cases as a group.
- Are there any clinical trials I qualify for? Trials are sometimes open to newly diagnosed men considering any path. Your team can search ClinicalTrials.gov for studies that match your profile.
If you are currently taking any prescription medications, or if you are pregnant or breastfeeding, speak with your oncologist or pharmacist before adding any supplement, herbal product, or over-the-counter product to your routine. This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.
